Aelix Therapeutics develops therapies for HIV as a spinout from Barcelona's HIVACAT Research Center. The company uses polynucleotide sequences from T-cells derived from HIV patients with naturally low viral loads, converted into DNA and delivered as a vaccine using a modified Ankara virus (MVA) as a vector. The vaccine has completed a Phase 1 trial. Founded in 2015 in Barcelona, Spain, the company has raised $12.6M in Series A funding from investors including Ysios Capital and Johnson & Johnson Innovation. It is a spinout from Barcelona's HIVACAT Research Center. The company plans to use polynucleotide sequences from T-cells derived from a cohort of HIV patients with naturally low viral loads.
← All startups
Aelix Therapeutics
Series AAelix Therapeutics develops therapies for HIV as a spinout from Barcelona's HIVACAT Research Center. The company uses polynucleotide sequences from T-cells derived from HIV patients with naturally low viral loads, converted into DNA and delivered as a vaccine using a modified Ankara virus (MVA) as a vector. The vaccine has completed a Phase 1 trial. Founded in 2015 in Barcelona, Spain, the company has raised $12.6M…
About
Business model
Infectious Diseases > Drugs > Viral > HIV,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
EIT HealthYsios CapitalCaixa Capital RiscJohnson & Johnson InnovationEuropa
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.